Pancreatic Cancer Research

ResearcherRoyal Stoke University HospitalActive in the last 2 years

Shahin Hajibandeh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6159-1068; OpenAlex author ID A5033322317, A5140395010. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2023: 3 papers · 2024: 5 papers · 2025: none · 2026: 5 papers

Papers 13

  1. Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2025.12.018↗
  2. Survival After Irreversible Electroporation in Unresectable Locally Advanced Pancreatic Cancer: A Meta-Analysis. Co-author DOI 10.1016/j.jss.2026.08.030↗
  3. Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis of Randomised Contro… Co-author DOI 10.1245/s10434-026-20319-7↗
  4. ASO Author Reflections: It is Time to Define an Optimal Duration of Neoadjuvant Treatment in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20436-3↗
  5. ASO Visual Abstract: Neoadjuvant Chemoradiotherapy versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis… Co-author DOI 10.1245/s10434-026-20533-3↗
  6. The role of adjuvant chemotherapy in management of stage I pancreatic ductal adenocarcinoma deserves independent high quality research. Co-author DOI 10.1002/jhbp.1409↗
  7. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2024.01.017↗
  8. Meta-analysis of survival after pulmonary resection for isolated metachronous pancreatic cancer metastasis: a promising, albeit infrequent, approach. Co-author DOI 10.1016/j.hpb.2024.05.015↗
  9. Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.11.027↗
  10. Meta-analysis of pancreatic re-resection for locally recurrent pancreatic cancer following index pancreatectomy. Co-author DOI 10.14701/ahbps.24-041↗
  11. Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis … First author DOI 10.14701/ahbps.22-052↗
  12. Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A Systematic Review. Co-author DOI 10.3390/biomedicines11071983↗
  13. Accuracy of the END-PAC Model in Predicting the Risk of Developing Pancreatic Cancer in Patients with New-Onset Diabetes: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/biomedicines11113040↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shahab Hajibandeh · 13 shared papers, 2023–2026 · strength 3.37
  2. David Christopher Bartlett · 6 shared papers, 2024–2026 · strength 1.67
  3. Robert Peter Sutcliffe · 6 shared papers, 2024–2026 · strength 1.67
  4. Keith John Roberts · 6 shared papers, 2023–2026 · strength 1.52
  5. Nikolaos A. Chatzizacharias · 5 shared papers, 2024–2026 · strength 1.36
  6. S.S. Raza · 5 shared papers, 2024–2026 · strength 1.36
  7. Tejinderjit Athwal · 4 shared papers, 2023–2024 · strength 1.07
  8. Thomas Satyadas · 4 shared papers, 2023–2026 · strength 0.81
  9. Daisy Evans · 2 shared papers, 2024 · strength 0.54
  10. Saurabh Jamdar · 1 shared paper, 2026 · strength 0.25
  11. Nicola de Liguori Carino · 1 shared paper, 2026 · strength 0.25
  12. Ajith Kumar Siriwardena · 1 shared paper, 2026 · strength 0.25
  13. Somaiah Aroori · 1 shared paper, 2023 · strength 0.17
  14. Daren A. Subar · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.